RESUMEN
Sacubitril/valsartan (LCZ696) is indicated for the treatment of patients with heart failure and reduced ejection fraction (HFrEF). Since patients with HFrEF may receive sacubitril/valsartan and sildenafil, both increasing cyclic guanosine monophosphate, the present study evaluated the pharmacokinetic and pharmacodynamic drug interaction potential between sacubitril/valsartan and sildenafil. In this open-label, three-period, single sequence study, patients with mild-to-moderate hypertension (153.8 ± 8.2 mmHg mean systolic blood pressure (SBP)) received a single dose of sildenafil 50 mg, sacubitril/valsartan 400 mg once daily for 5 days, and sacubitril/valsartan and sildenafil coadministration. When coadministered with sildenafil, the AUC and Cmax of valsartan decreased by 29% and 39%, respectively. Coadministration of sacubitril/valsartan and sildenafil resulted in a greater decrease in BP (-5/-4/-4 mmHg mean ambulatory SBP/DBP/MAP (mean arterial pressure)) than with sacubitril/valsartan alone. Both treatments were generally safe and well tolerated in this study; however, the additional BP reduction suggests that sildenafil should be administered cautiously in patients receiving sacubitril/valsartan. Unique identifier: NCT01601470.
Asunto(s)
Aminobutiratos/farmacología , Aminobutiratos/farmacocinética , Antagonistas de Receptores de Angiotensina/farmacología , Antagonistas de Receptores de Angiotensina/farmacocinética , Antihipertensivos/farmacología , Antihipertensivos/farmacocinética , Hipertensión/tratamiento farmacológico , Citrato de Sildenafil/farmacología , Citrato de Sildenafil/farmacocinética , Tetrazoles/farmacología , Tetrazoles/farmacocinética , Aminobutiratos/efectos adversos , Antagonistas de Receptores de Angiotensina/efectos adversos , Antihipertensivos/efectos adversos , Factor Natriurético Atrial/orina , Compuestos de Bifenilo , Presión Sanguínea/efectos de los fármacos , GMP Cíclico/orina , Método Doble Ciego , Combinación de Medicamentos , Interacciones Farmacológicas , Humanos , Masculino , Persona de Mediana Edad , Citrato de Sildenafil/efectos adversos , Tetrazoles/efectos adversos , ValsartánRESUMEN
Metabolic syndrome, a cluster of risk factors that increase the risk of cardiovascular morbidity and mortality, is common in patients with hypertension. Chronic renin-angiotensin-aldosterone system (RAAS) activation, shown by elevated plasma renin activity (PRA), is implicated in many of the features of metabolic syndrome. The direct renin inhibitor aliskiren may be of benefit in this patient group as aliskiren targets the RAAS at the rate-limiting step. In this double-blind study, 141 patients with hypertension (mean baseline BP 155/93 mm Hg) and metabolic syndrome (modified National Cholesterol Education Program ATP III criteria) were randomized to aliskiren 300 mg or irbesartan 300 mg once daily. Patients treated with aliskiren 300 mg had their mean sitting blood pressure (BP) lowered by 13.8/7.1 mm Hg after 12 weeks, significantly greater (P≤0.001) than the 5.8/2.8 mm Hg reduction observed in patients treated with irbesartan 300 mg. A significantly greater proportion of patients treated with aliskiren achieved BP control to <135/85 mm Hg (29.2 vs 16.7% with irbesartan; P=0.019). Aliskiren treatment led to a 60% decrease in PRA from baseline, whereas irbesartan increased PRA by 99% (both P<0.001). Aliskiren and irbesartan had similar effects on glucose and lipid profiles and on a panel of biomarkers of inflammation and cardiovascular risk. Both aliskiren and irbesartan were well tolerated. Collectively, these results suggest that aliskiren 300 mg may offer treatment benefits compared with irbesartan 300 mg for BP reduction in patients with hypertension and metabolic syndrome.
Asunto(s)
Amidas/uso terapéutico , Antihipertensivos/uso terapéutico , Compuestos de Bifenilo/uso terapéutico , Fumaratos/uso terapéutico , Hipertensión/tratamiento farmacológico , Síndrome Metabólico/tratamiento farmacológico , Tetrazoles/uso terapéutico , Adulto , Anciano , Glucemia/efectos de los fármacos , Enfermedades Cardiovasculares/tratamiento farmacológico , Método Doble Ciego , Femenino , Humanos , Inflamación/sangre , Irbesartán , Lípidos/sangre , Masculino , Persona de Mediana Edad , Renina/sangre , Sistema Renina-Angiotensina/efectos de los fármacos , Resultado del TratamientoRESUMEN
OBJECTIVES: The object of the present study is to determine whether native (n) low-density lipoprotein (LDL) isolated from men with type II diabetes and abnormal endothelial function inhibits endothelium-dependent relaxation more than n-LDL isolated from nondiabetic control subjects. BACKGROUND: Endothelium-dependent vasodilation is impaired in men with type II diabetes and this may result from qualitative rather than quantitative abnormalities of LDL. METHODS: Forearm blood flow responses to brachial artery infusions of acetylcholine (endothelium-dependent vasodilator) and nitroprusside (endothelium-independent vasodilator) were measured in 10 men with uncomplicated type II diabetes and 10 nondiabetic men of similar age and with similar plasma concentrations of LDL cholesterol. Native LDL was isolated by discontinuous density gradient ultracentrifugation using EDTA to prevent oxidation. Preconstricted rabbit aortic ring bioassay was used to determine inhibitory properties of n-LDL on endothelium-dependent relaxation by measuring relaxation to acetylcholine (and nitroprusside) in the presence and absence of n-LDL. RESULTS: Forearm blood flow responses to acetylcholine but not nitroprusside were significantly impaired (p < 0.01) in diabetic men compared with control subjects. Native LDL (10 and 100 microg protein/ml) from diabetic men inhibited relaxation to acetylcholine by 13.9 +/- 4.8% and 61.9 +/- 7.8% (mean inhibition for all doses +/- SE), respectively, whereas n-LDL from control subjects inhibited relaxation by 7.3 +/- 3.0% and 23.9 +/- 5.7% (p < 0.01 for a difference between diabetic and control n-LDL). Relaxation to nitroprusside was not significantly inhibited by n-LDL. CONCLUSIONS: A qualitative abnormality of LDL may account for endothelial dysfunction in men with type II diabetes.
Asunto(s)
LDL-Colesterol/sangre , Diabetes Mellitus Tipo 2/fisiopatología , Angiopatías Diabéticas/fisiopatología , Endotelio Vascular/fisiopatología , Vasodilatación/fisiología , Acetilcolina , Animales , Técnicas de Cultivo , Antebrazo/irrigación sanguínea , Humanos , Masculino , Persona de Mediana Edad , Nitroprusiato , ConejosRESUMEN
BACKGROUND: Small low-density lipoprotein (LDL) particle size, a newly recognized risk factor for cardiovascular disease in the general population, is frequently associated with hypertriglyceridaemia, the predominant plasma lipid abnormality present in uraemia. METHODS: Plasma lipids and LDL subfraction profiles were examined in 33 non-dialysed patients with chronic renal failure (predial), 40 patients on continuous ambulatory peritoneal dialysis (CAPD), 42 haemodialysis patients (HD), 47 renal transplant recipients (RTR), and 44 controls. LDL subfractions separated by gel electrophoresis were scored by densitometric analysis (higher scores indicate profiles comprising smaller particles). RESULTS: All groups with renal failure had significantly elevated (mean+/-SD) LDL scores (predial 1.36+/-0.6, CAPD 1.71+/-0.9, HD 1.68+/-0.9, RTR 1.92+0.8 vs control 0.87+0.4, all P<0.001), this being the only lipid abnormality detected in the predialysis patients. In CAPD and HD patients, LDL scores were associated with serum triglyceride (r=0.81, P<0.001 and r=0.70, P<0.001 respectively), cholesterol (r=0.55, P<0.001 and r=0.49, P<0.01) and HDL-cholesterol (r= -0.43, P<0.01 and r= -0.51, P<0.01), whilst no such relationship was seen in the predialysis and RTR groups, suggesting that other factors were important. CONCLUSIONS: The presence of small LDL particles appears to be an early and unexplained feature of the uraemic dyslipidaemia. This abnormality persists after renal transplantation and may represent an important atherogenic risk factor.
Asunto(s)
Fallo Renal Crónico/sangre , Lipoproteínas LDL/sangre , Antagonistas Adrenérgicos beta/uso terapéutico , Adulto , Anciano , Diuréticos/uso terapéutico , Femenino , Humanos , Inmunosupresores/uso terapéutico , Fallo Renal Crónico/terapia , Lípidos/sangre , Lipoproteínas/sangre , Lipoproteínas LDL/química , Masculino , Persona de Mediana Edad , Tamaño de la Partícula , Diálisis Peritoneal Ambulatoria Continua , Diálisis RenalRESUMEN
In a prospective longitudinal study in 17 women, we investigated the effects of surgical menopause and subsequent oestrogen-only hormone replacement therapy (HRT) on plasma concentrations of total cholesterol, HDL cholesterol, LDL cholesterol, triglyceride and LDL subfractions profile. Plasma LDL is a heterogeneous population of particles of varying size, density and chemical composition. The predominance of small LDL particles is a newly-recognized risk factor for coronary artery disease. The LDL score is used to describe LDL subfractions profile and the greater the score, the higher the proportion of small LDL particles. Six weeks after hysterectomy and bilateral oopherectomy, total cholesterol and triglyceride concentrations were significantly increased (p < 0.01) as well as the LDL score (p < 0.05). After 6 weeks of oestrogen-only HRT, total cholesterol concentration was significantly lower and HDL cholesterol concentration significantly higher than before the treatment (p < 0.05). At the same time, mean LDL score significantly increased and in none of the women did LDL subfractions profile change favourably.
Asunto(s)
Terapia de Reemplazo de Estrógeno , Lipoproteínas LDL/sangre , Menopausia/sangre , Adulto , Colesterol/sangre , HDL-Colesterol/sangre , Femenino , Hormonas Esteroides Gonadales/sangre , Humanos , Histerectomía , Persona de Mediana Edad , Ovariectomía , Periodo Posoperatorio , Estudios Prospectivos , Triglicéridos/sangreRESUMEN
There is an increasing interest in low density lipoprotein (LDL) subfractions since some of them are associated with a higher risk for coronary artery disease (CAD). Small LDL particles are particularly atherogenic and more of those are produced in hypertriglyceridaemia. However, high triglyceride concentrations are not the only explanation for the predominance of small LDL particles and other influences, including genetic factors, are also responsible for LDL particle size. We investigated LDL subfraction profiles in two groups: 46 men with and 21 men without CAD proven angiographically. For the separation of LDL subfractions, we used continuous disc polyacrylamide gel electrophoresis (PAGE) that is rapid and easier to perform than the other methods usually used which, although more precise in terms of measuring particle diameter, are much more demanding of time and equipment. The described method is suitable for routine use in assessing large numbers of patients. All studied men had triglyceride concentrations below 2.3 mmol/l. LDL scores were calculated on the basis of all LDL subfractions present in a particular profile; the higher the score, the greater the proportion of small LDL particles. LDL cholesterol (P < 0.05) and LDL score (P < 0.001) were the only significant discriminators between two groups. LDL score was significantly correlated with CAD, even after adjusting for triglyceride and HDL cholesterol concentrations and it was the best discriminant factor for the presence of CAD.
Asunto(s)
Enfermedad Coronaria , Lipoproteínas LDL/sangre , Triglicéridos/sangre , Humanos , Lípidos/sangre , Lipoproteínas LDL/clasificación , Masculino , Persona de Mediana Edad , Valores de Referencia , Factores de RiesgoRESUMEN
Using different analytical methods, up to 12 low-density lipoprotein (LDL) subfractions can be separated. LDL particle size decreases with increasing density. Smaller, denser LDL particles seem more atherogenic than the larger, lighter particles, based on the experimental findings that smaller LDL particles are more susceptible for oxidation in vitro, have lower binding affinity for the LDL receptors and lower catabolic rate, have a higher concentration of polyunsaturated fatty acids, and potentially interact more easily with proteoglycans of the arterial wall. Clinical studies have shown that a smaller LDL subfraction profile is associated with an increased risk of heart disease, even when total cholesterol level is only slightly raised. There is a strong inverse association between LDL particle size and triglyceride concentrations. Although LDL particle size is genetically determined, its phenotypic expression may also be affected by environmental factors such as drugs, diet, obesity, exercise or disease. Factors that shift the LDL subfractions profile towards larger particles may reduce the risk of heart disease.
Asunto(s)
Arteriosclerosis/etiología , Lipoproteínas LDL/química , Arterias/patología , Arteriosclerosis/metabolismo , Arteriosclerosis/patología , Enfermedad Coronaria/metabolismo , Humanos , Lipoproteínas LDL/metabolismo , Hígado/metabolismo , Tamaño de la PartículaAsunto(s)
Enfermedad Coronaria/prevención & control , Antiarrítmicos/uso terapéutico , Antihipertensivos/uso terapéutico , Antioxidantes/uso terapéutico , Terapia de Reemplazo de Estrógeno , Femenino , Fibrinolíticos/uso terapéutico , Humanos , Hipolipemiantes/uso terapéutico , Masculino , Persona de Mediana Edad , PosmenopausiaRESUMEN
Celiprolol is a third-generation beta-adrenoceptor blocker with selective beta 1-antagonist, partial beta 2-agonist and mild alpha 2-antagonist actions. It seems to be as effective as other beta-blockers in the treatment of hypertension and angina pectoris. beta-Blockers have many cardioprotective effects and have been shown to reduce the morbidity and mortality from coronary artery disease in a number of trials. However, there is no good clinical evidence that celiprolol itself has specific cardioprotective properties other than those attributable to this class of drugs. Because of its pharmacological profile, celiprolol is less likely to cause bradycardia, deterioration in cardiac function and other adverse effects mainly caused by beta 2-blockade. Unlike most other beta-blockers, celiprolol has no adverse effects on plasma lipids. It seems to be well tolerated in diabetic patients and patients with renal dysfunction.
Asunto(s)
Antagonistas Adrenérgicos beta/farmacología , Enfermedades Cardiovasculares/tratamiento farmacológico , Celiprolol/uso terapéutico , Antagonistas Adrenérgicos beta/efectos adversos , Metabolismo de los Hidratos de Carbono , Celiprolol/efectos adversos , Tolerancia a Medicamentos , Fibrinógeno/metabolismo , Corazón/efectos de los fármacos , Humanos , Riñón/efectos de los fármacos , Sistema Respiratorio/efectos de los fármacos , Factores de RiesgoRESUMEN
Sudden cardiac death is a major health problem in the industrially developed countries. The risk of sudden cardiac death may be reduced by early detection of coronary heart disease, elimination of the risk factors, treatment of the ischaemia in patients known to have coronary heart disease and suppression of ventricular arrhythmias. Of all the therapeutic measures currently available to reduce the risk of sudden cardiac death, beta-adrenoceptor-blocking drugs (beta blockers) appear to be the most effective. In this paper their actions are reviewed and evidence for their efficacy is presented.
Asunto(s)
Antagonistas Adrenérgicos beta/uso terapéutico , Muerte Súbita Cardíaca/prevención & control , Adulto , Enfermedad Coronaria/complicaciones , Enfermedad Coronaria/prevención & control , Muerte Súbita Cardíaca/etiología , Humanos , Masculino , Persona de Mediana EdadRESUMEN
Cases of fixed drug eruption due to trimethoprim-sulfamethoxazole combination are reported. In these cases the oral mucous membranes were affected. Fixed drug eruption is a distinct entity characterized by the development of circular erythematous lesions which over a period of time becomes violaceous. Sulfamethoxazole is probably the main cause of this drug eruption but there are some reports that trimethoprim itself can cause them too.